This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05645692
Recruitment Status : Recruiting
First Posted : December 9, 2022
Last Update Posted : April 16, 2024
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.

Condition or disease Intervention/treatment Phase
Urothelial Cancer Drug: Atezolizumab Drug: Tobemstomig Drug: Tiragolumab Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
Actual Study Start Date : April 13, 2023
Estimated Primary Completion Date : December 30, 2026
Estimated Study Completion Date : December 30, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm A
Participants will receive intravenous (IV) atezolizumab every 3 weeks (Q3W).
 Drug: Atezolizumab
Participants will receive 1200 mg IV atezolizumab Q3W.
Experimental: Arm B
Participants will receive IV tobemstomig Q3W.
 Drug: Tobemstomig
Participants will receive 600 mg IV tobemstomig Q3W.
Other Name: RO7247669
Experimental: Arm C
Participants will receive IV tobemstomig + IV tiragolumab Q3W.
 Drug: Tobemstomig
Participants will receive 600 mg IV tobemstomig Q3W.
Other Name: RO7247669

Drug: Tiragolumab
Participants will receive 600 mg IV tiragolumab Q3W.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Confirmed Objective Response Rate (ORR) [ Time Frame: Up to approximately 30 months ]

Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Up to approximately 30 months ]
  2. Overall Survival (OS) [ Time Frame: Up to approximately 30 months ]
  3. Duration of Response (DOR) [ Time Frame: Up to approximately 30 months ]
  4. PFS [ Time Frame: 6 months and 12 months ]
  5. OS [ Time Frame: 6 months, 12 months, and 18 months ]
  6. Disease Control Rate (DCR) [ Time Frame: Up to 12 weeks ]
  7. Time to Confirmed Deterioration (TTCD) [ Time Frame: Baseline up to 3 weeks ]
  8. Change from Baseline in European Organisation for Research and Cancer Treatment Item Library 187 (EORTC IL 187) Scores [ Time Frame: Up to approximately 30 months ]
  9. Maximum Concentration (Cmax) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  10. Time of Maximum Concentration (Tmax) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  11. Clearance (CL) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  12. Volume of Distribution at Steady State (Vss) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  13. Area Under the Curve (AUC) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  14. Half-Life (T1/2) of Tobemstomig [ Time Frame: Up to approximately 30 months ]
  15. Maximum serum concentration (Cmax) of tiragolumab [ Time Frame: Up to approximately 30 months ]
  16. Minimum serum concentration (Cmin) of tiragolumab [ Time Frame: Up to approximately 30 months ]
  17. Cmax of atezolizumab [ Time Frame: Up to approximately 30 months ]
  18. Cmin of atezolizumab [ Time Frame: Up to approximately 30 months ]
  19. Incidence of Anti-Drug Antibodies (ADAs) [ Time Frame: Up to approximately 30 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
  • Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Participants with squamous, sarcomatoid, micropapillary, and glandular variant histologies are eligible for inclusion in the study, provided that a urothelial component is present in the tumor specimen. Participants with other variant histologies or pure variant histologies are not eligible for inclusion in this study
  • Ineligible ("unfit") to receive platinum-based chemotherapy
  • No prior chemotherapy for inoperable locally advanced or metastatic or recurrent urothelial carcinoma (UC)
  • Measurable disease; at least one measurable lesion as defined by response evaluation criteria in solid tumors, version 1.1 (RECIST v1.1)
  • Availability of a representative leftover tumor specimen that is suitable for determination of PD-L1 status as assessed by a central laboratory
  • Adequate hematologic and end organ function
  • Negative for hepatitis B and hepatitis C virus (HCV)
  • Adequate cardiovascular function

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • GFR <15 mL/min/1.73 m2
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • History of leptomeningeal disease
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled or symptomatic hypercalcemia
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Active tuberculosis (TB) or acute Epstein-Barr virus (EBV)
  • Significant cardiovascular/cerebrovascular disease within 3 months prior to initiation of study treatment
  • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • History of another primary malignancy other than urothelial carcinoma within 2 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with therapeutic oral or intravenous antibiotics within 2 weeks prior to initiation of study treatment. Participants receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease [COPD] exacerbation), or who are receiving oral antibiotics to treat a urinary tract infection are eligible for the study
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment or within 5 months after the final dose of atezolizumab, 4 months after the final dose of tobemstomig, or 90 days after the final dose of tiragolumab
  • Current treatment with anti-viral therapy for HBV
  • Treatment with any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Treatment with investigational therapy within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-TIGIT and anti-LAG3 therapeutic antibodies or pathways targeting agents
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives prior to initiation of study treatment
  • Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05645692


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BO44157 https://forpatients.roche.com/ 888-662-6728 global-roche-genentech-trials@gene.com

Locations
Show Show 80 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-LaRoche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT05645692    
Other Study ID Numbers: BO44157
First Posted: December 9, 2022    Key Record Dates
Last Update Posted: April 16, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atezolizumab
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Antineoplastic Agents